Now, Paramount Primal, Paramount's smartly-budgeted genre label formed by producers J.D. Lifshitz and Raphael Margules, has ...

It's the latest project acquired by the studio's new fast-moving genre label.

John Carpenter, Colman Domingo and Charlize Theron will be the honorees at the Academy Museum of Motion Pictures Gala, to take place on Oct. 17, 2026. The Academy Museum made the ...

Shares of Scribe Therapeutics, a genetic-medicines company co-founded by Nobel laureate Jennifer Doudna, shot up on their first day of trading Friday, continuing a rebound for biotech IPOs this year.

This article first appeared on GuruFocus. Scribe Therapeutics (NASDAQ:SCTX), a clinical-stage developer of gene therapies for heart disease, surged 67% on Friday after raising $128.7 million in an ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

For many people, managing a disease means chronic therapy. Scribe Therapeutics has a different vision: genetic medicines that offer durable effects for the masses. With its lead program on a path to ...

IndieWire compares IMAX, 70mm IMAX, 70mm, 35mm, 4DX and Dolby Vision to determine which format provides the best way to watch and hear Nolan's epic.

Scribe Therapeutics Inc. (SCTX) has filed to raise drug development investment in an IPO, according to an S-1 registration statement. The firm is a clinical-stage biopharma developing gene editing ...

Scribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing. The Bay Area biotech already disclosed earlier this ...

American biologist Kent Carpenter, 73, was shot and killed at his home in the Philippines on Sunday in what authorities are calling a murder. Carpenter, an adjunct professor at Silliman University's ...

Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials. While the Bay Area biotech has yet to set ...